Abstract

Indonesia has been facing COVID-19 since March 2020, causing significant problems for public health. Indonesia is trying to solve this problem, and the vaccination program began in January 2021. Several obstacles include public acceptance of the composition of the COVID-19 vaccine. We systematically searched peer-reviewed studies during 2020-2022, examining analyses of the Chemical Composition of the COVID-19 Vaccine authorized in Indonesia. We also explored the related information from the official body. Finally, we constructed a short review of the public acceptance of the vaccine focusing on the chemical composition. All COVID-19 vaccines are intended to induce humoral and cellular immunity toward infection. The antigen causes this as an active ingredient of the vaccine. The vaccine also contains adjuvants, and some other chemicals are required. The expansion aims to maintain the content of the vaccine, strengthen the body's reaction to the vaccine, and facilitate the administration process. But there are concerns about the risk of unintended effects of the substances used. This perception includes those that hinder the implementation of COVID-19 Vaccination in Indonesia. There is a need to disseminate information and education about the vaccine composition so that the optimal vaccination program benefits the community.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call